Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning
Karlsson, L.; Strandberg, O.; Smith, R.; Tang, W.; Arvidsson, I.; Astrom, K.; Oliviera Hauer, K.; Janelidze, S.; Stomrud, E.; Palmqvist, S.; Verghese, P. B.; Braunstein, J. B.; Alzheimer's Disease Neuroimaging Initiative, ; PREVENT-AD Research Group, ; Klein, G.; Shcherbinin, S.; Jagust, W. J.; Villeneuve, S.; La Joie, R.; Rabinovici, G. D.; Mattsson-Carlgren, N.; Vogel, J. W.; Hansson, O.
Show abstract
Tau protein aggregation in the brain is a hallmark of Alzheimers disease (AD). Positron emission tomography (PET) is the only in vivo method to visualize tau pathology and estimate both its burden and regional distribution, but the use of tau-PET is constrained by high cost and limited accessibility. Here, we develop a deep learning model to synthesize tau-PET scans from more accessible data: structural magnetic resonance imaging (MRI), demographics, and when available, blood biomarkers. We included 5,191 participants across the AD continuum or with another neurological disorder from 13 cohorts (mean age 70 years, 51% female) and optimized a 3D U-Net neural network with residual and attention units for this task. In held-out test data, synthetic tau-PET reliably modeled tau burden, with correlations of R=0.77-0.86 with true tau-PET across individuals in common AD regions of interest. Spatial similarity between synthetic and true tau-PET was likewise high, with mean regional correlation of R=0.75. Synthetic scans also captured clinically meaningful prognostic information comparable to true tau-PET, including distinction between early (HR=12, p<0.001) and late (HR=45, p<0.001) stages of tau accumulation. These findings demonstrate that clinically informative synthetic tau-PET scans can be generated from widely available modalities using deep learning, potentially offering a scalable and cost-effective approach for estimating tau AD pathology in the brain.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- AI-driven fusion of neurological work-up for assessment of biological Alzheimer’s disease 98%
- Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer 97%
- Hemispheric Asymmetry of Tau Pathology is Related to Asymmetric Amyloid Deposition in Alzheimer's Disease 97%
Similar papers in this journal
- Prediction of brain age using structural magnetic resonance imaging: A comparison of clinical validity of publicly available software packages 93%
- The ratio of plasma pTau181 and pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosis 92%
- Rates of regional tau accumulation in ageing and across the Alzheimer’s disease continuum: An AIBL 18 F-MK6240 PET study 91%
Similar papers in this journal
- Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease 97%
- Head-to-head comparison between plasma p-tau217 and Flortaucipir-PET in amyloid-positive patients with cognitive impairment 96%
- Tau-PET and in vivo Braak-staging as a prognostic marker in Alzheimer’s disease 96%